Czechia SUKL · July 27, 2026

New treatment option for neovascular (wet) age-related macular degeneration

Original title: Nová možnost léčby neovaskulární (vlhké) formy věkem podmíněné makulární degenerace

EMA recommended marketing authorisation for Susvimo (ranibizumab) in the European Union.

Low obligation Product class Pharmaceuticals Czech Republic Pharmaceuticals

Agentura EMA doporučila udělit registraci přípravku Susvimo (ranibizumab) v Evropské unii.

Read the official source ↗

Published by Czechia SUKL. HealthSignal links to the original document; the summary above is extracted from the source text.